MetLife Investment Management LLC Sells 3,726 Shares of Lifecore Biomedical, Inc. $LFCR

MetLife Investment Management LLC trimmed its position in shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR) by 25.7% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,787 shares of the company’s stock after selling 3,726 shares during the quarter. MetLife Investment Management LLC’s holdings in Lifecore Biomedical were worth $76,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Northern Trust Corp lifted its holdings in shares of Lifecore Biomedical by 14.5% during the 4th quarter. Northern Trust Corp now owns 221,498 shares of the company’s stock valued at $1,646,000 after buying an additional 28,019 shares during the period. Bank of America Corp DE increased its stake in shares of Lifecore Biomedical by 25.3% in the 4th quarter. Bank of America Corp DE now owns 33,507 shares of the company’s stock worth $249,000 after purchasing an additional 6,776 shares in the last quarter. XTX Topco Ltd purchased a new stake in shares of Lifecore Biomedical in the 1st quarter worth $145,000. Hurley Capital LLC purchased a new stake in shares of Lifecore Biomedical in the 1st quarter worth $35,000. Finally, Boston Partners purchased a new stake in shares of Lifecore Biomedical in the 1st quarter worth $241,000. 83.36% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently commented on LFCR shares. William Blair started coverage on Lifecore Biomedical in a research note on Wednesday, May 21st. They issued an “outperform” rating for the company. KeyCorp started coverage on Lifecore Biomedical in a research note on Wednesday, September 3rd. They issued a “sector weight” rating for the company. Finally, Wall Street Zen upgraded Lifecore Biomedical from a “sell” rating to a “hold” rating in a research note on Saturday, August 16th. Two investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $8.00.

Lifecore Biomedical Trading Down 3.4%

Shares of Lifecore Biomedical stock opened at $7.01 on Thursday. The firm has a market cap of $262.24 million, a price-to-earnings ratio of -5.35 and a beta of 0.64. The business has a 50-day moving average price of $7.57 and a 200-day moving average price of $6.95. The company has a quick ratio of 1.77, a current ratio of 2.84 and a debt-to-equity ratio of 113.76. Lifecore Biomedical, Inc. has a twelve month low of $4.33 and a twelve month high of $8.85.

Lifecore Biomedical (NASDAQ:LFCR) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). The firm had revenue of $36.44 million for the quarter, compared to analysts’ expectations of $35.36 million. Lifecore Biomedical had a negative net margin of 31.70% and a negative return on equity of 846.51%. Lifecore Biomedical has set its FY 2026 guidance at EPS. Equities research analysts anticipate that Lifecore Biomedical, Inc. will post -0.91 EPS for the current fiscal year.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.